■随着乳腺癌(BC)治疗的最新进展,患者的无病生存期(DFS)正在增加,复发和转移的危险因素正在改变.然而,目前缺乏一种动态方法来评估BC复发转移的风险.本研究旨在基于条件生存(CS)分析开发一种动态变化的复发转移预测模型。
■回顾性分析2011年8月至2022年8月在青岛大学附属医院接受手术治疗的BC患者的临床和病理资料。使用CS分析计算具有不同生存率的患者的复发和转移风险,并构建了风险预测模型。
■本研究共纳入4244例患者,中位随访时间为83.16±31.59个月。我们的研究结果表明,患者的实时DFS随着时间的推移而增加,手术后DFS的可能性与既往生存年数相关。我们探讨了基线患者复发转移的不同危险因素,3年,和5年无病幸存者,发现低HER2是5年DFS患者随后复发的危险因素。基于此,开发了条件列线图。列线图显示了对BC患者复发和转移的良好预测能力。
■我们的研究表明,BC患者保持无病的时间越长,他们再次保持无病的机会就越大。基于CS分析的复发和转移风险预测模型可以帮助提高患者对抗癌症的信心,并帮助医生个性化治疗和随访计划。
乳腺癌的条件生存随着乳腺癌(BC)治疗的最新进展,患者的无病生存率正在提高,复发和转移的危险因素正在发生变化。其中一个关键的危险因素是人表皮生长因子受体2(HER2)。然而,最近出现的抗HER2抗体-药物偶联物(ADC)对传统的基于HER2的二元分类提出了挑战.传统HER2阴性组的患者现在可以进一步分类为HER2低(ISH阴性,IHC1或IHC2)或HER2-0(ISH阴性和IHC-0)。这种分类对BC的预后也有一定的价值吗?我们回顾性分析2011年8月至2022年8月在青岛大学附属医院接受手术治疗的BC患者的临床和病理资料.使用条件生存分析计算具有不同生存率的患者的复发和转移风险,并构建了风险预测模型。我们的研究结果表明,患者的实时无病生存(DFS)随着时间的推移而增加,手术后DFS的可能性与既往生存年数相关。为基线患者开发条件列线图,3年和5年无病幸存者。列线图显示了对BC患者复发和转移的良好预测能力。
UNASSIGNED: With recent advances in breast cancer (BC) treatment, the disease-free survival (DFS) of patients is increasing and the risk factors for recurrence and metastasis are changing. However, a dynamic approach to assessing the risk of recurrent metastasis in BC is currently lacking. This study aimed to develop a dynamically changing prediction model for recurrent metastases based on conditional survival (CS) analysis.
UNASSIGNED: Clinical and pathological data from patients with BC who underwent surgery at the Affiliated Hospital of Qingdao University between August 2011 and August 2022 were retrospectively analysed. The risk of recurrence and metastasis in patients with varying survival rates was calculated using CS analysis, and a risk prediction model was constructed.
UNASSIGNED: A total of 4244 patients were included in this study, with a median follow-up of 83.16 ± 31.59 months. Our findings suggested that the real-time DFS of patients increased over time, and the likelihood of DFS after surgery correlated with the number of years of prior survival. We explored different risk factors for recurrent metastasis in baseline patients, 3-year, and 5-year disease-free survivors, and found that low HER2 was a risk factor for subsequent recurrence in patients with 5-year DFS. Based on this, conditional nomograms were developed. The nomograms showed good predictive ability for recurrence and metastasis in patients with BC.
UNASSIGNED: Our study showed that the longer patients with BC remained disease-free, the greater their chances of remaining disease-free again. Predictive models for recurrence and metastasis risk based on CS analysis can help improve the confidence of patients fighting cancer and help doctors personalise treatment and follow-up plans.
Conditional survival in breast cancer With recent advances in breast cancer (BC) treatment, the disease-free survival of patients is increasing and the risk factors for recurrence and metastasis are changing. One of the key risk factor is the human epidermal growth factor receptor 2 (HER2). However, the recent advent of anti-HER2 antibody-drug conjugates (ADC) has challenged the traditional binary classification based on HER2. Patients in the traditional HER2-negative group can now be further classified as HER2-low (ISH-negative with IHC1 or IHC2) or HER2-0 (ISH-negative and IHC-0). Does this categorisation also have some value for the prognosis of BC? To figure this out, we retrospectively analysed the clinical and pathological data of BC patients who underwent surgery at the Affiliated Hospital of Qingdao University between August 2011 and August 2022. The risk of recurrence and metastasis in patients with varying survival rates was calculated using conditional survival analysis, and a risk prediction model was constructed.Our findings suggested that the real-time disease-free survival (DFS) of patients increased over time, and the likelihood of DFS after surgery correlated with the number of years of prior survival. Conditional nomograms were developed for baseline patients, 3-year and 5-year disease-free survivors. The nomograms showed good predictive ability for recurrence and metastasis in patients with BC.